Lund SS - Search Results

1

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA. Lund SS, et al. Eur J Endocrinol. 2008 Jan;158(1):35-46. doi: 10.1530/EJE-07-0500. Eur J Endocrinol. 2008. PMID: 18166815 Clinical Trial.

2

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.

Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA. Lund SS, et al. PLoS One. 2008;3(10):e3363. doi: 10.1371/journal.pone.0003363. Epub 2008 Oct 9. PLoS One. 2008. PMID: 18852875 Free PMC article. Clinical Trial.

3

Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?

Vaag A, Lund SS. Vaag A, et al. Among authors: lund ss. Appl Physiol Nutr Metab. 2007 Oct;32(5):912-20. doi: 10.1139/H07-100. Appl Physiol Nutr Metab. 2007. PMID: 18059616 Free article.

4

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, Winther K, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA. Lund SS, et al. Eur J Endocrinol. 2008 May;158(5):631-41. doi: 10.1530/EJE-07-0815. Eur J Endocrinol. 2008. PMID: 18426821 Clinical Trial.

5

Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.

Hemmingsen B, Lund SS, Wetterslev J, Vaag A. Hemmingsen B, et al. Among authors: lund ss. Eur J Endocrinol. 2009 Jul;161(1):1-9. doi: 10.1530/EJE-09-0167. Epub 2009 Apr 15. Eur J Endocrinol. 2009. PMID: 19369429 Review.

6

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.

Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA. Lund SS, et al. BMJ. 2009 Nov 9;339:b4324. doi: 10.1136/bmj.b4324. BMJ. 2009. PMID: 19900993 Free PMC article. Clinical Trial.

7

Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus.

Lund SS, Petersen M, Frandsen M, Smidt UM, Parving HH, Vaag AA, Jensen T. Lund SS, et al. Clin Chem. 2011 Feb;57(2):298-308. doi: 10.1373/clinchem.2009.133868. Epub 2010 Oct 14. Clin Chem. 2011. PMID: 20947697

8

Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.

Engelen L, Lund SS, Ferreira I, Tarnow L, Parving HH, Gram J, Winther K, Pedersen O, Teerlink T, Barto R, Stehouwer CD, Vaag AA, Schalkwijk CG. Engelen L, et al. Among authors: lund ss. Eur J Endocrinol. 2011 Mar;164(3):371-9. doi: 10.1530/EJE-10-0851. Epub 2011 Jan 4. Eur J Endocrinol. 2011. PMID: 21205874 Clinical Trial.

9

Insulin regimens in type 2 diabetes.

Lund SS, Vaag AA. Lund SS, et al. N Engl J Med. 2010 Mar 11;362(10):959; author reply 960. doi: 10.1056/NEJMc0911551. N Engl J Med. 2010. PMID: 20220196 No abstract available.

10

[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].

Hemmingsen B, Lund SS, Vaag A. Hemmingsen B, et al. Among authors: lund ss. Ugeskr Laeger. 2009 May 4;171(19):1598-602. Ugeskr Laeger. 2009. PMID: 19419642 Review. Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page